OLAMIDE ADELEYE: Open Payments
NPI 1225379050 · SOUTHAVEN, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$305 in 12 payments from 6 companies in 2025. Trend: 2023 $692 · 2024 $773 · 2025 $305
Food & beverage: $305
| Company | Payments | Amount |
|---|---|---|
| Ardelyx, Inc. | 2 | $64 |
| AstraZeneca Pharmaceuticals LP | 3 | $60 |
| Novartis Pharmaceuticals Corporation | 2 | $58 |
| Lilly USA, LLC | 2 | $55 |
| Vifor Pharma, Inc. | 2 | $45 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 1 | $23 |
Products named: JARDIANCE, IBSRELA, Vanrafia, Veltassa, LOKELMA, FARXIGA.
Industry payments across MS — which companies pay providers there.
